LD Micro: Assembly Biosciences Becomes Event Driven

Chris Lahiji  |

Image: Assembly Biosciences

Impact.

Highlighting Anomalies Amongst the Week’s Biggest Gainers, Losers, & Volume Leaders.

by Christian Galatti (Phase 4 Research)

Assembly Biosciences...+73% for the Week.

The Company Becomes Event Driven.

Click to enlarge

Story.

From 2016 to 2018 Assembly Biosciences could do no wrong (see chart.) Getting closer to a cure for Hepatitis B gave the stock momentum that lasted, and lasted and lasted. Allowing them to raise $144M last July at $36 on the way down when the trial data became less sublime. A raise that paid for research that was meant to stop the bleeding. Baird stated in an initiation piece in August 2018 at $38 that ASMB would almost double to $74 shortly. While not understanding the true market forces that would take the stock straight to $9.

Baird Initiates Coverage On Assembly Biosciences with Outperform Rating,

Announces $74 Price Target, August 08, 2018

While not a cure, Assembly Bio’s product does work. It works well enough that it may be the best thing out there. Clinical data showing that the virus was reduced in just two weeks was good enough for the stock to make the biggest gainer list this week with a 72% gain after hitting lows.

Shares of Assembly Biosciences (NASDAQ:ASMB) gained over 41% today after the company announced an update on its hepatitis B virus (HBV) programs.

The first update, from a phase 2a study evaluating the lead drug candidate ABI-H0731, suggests that the pipeline asset is effective in reducing DNA and RNA signatures of the virus. The second update, from a phase 1b study of a next-generation drug candidate named ABI-H2158, suggests that the asset can reduce the activity of the virus after just 14 days.

ASMB has become an event driven stock. More data is coming out on November 11th. An event that’s worth the following quote as the story is about to continue through the end of the year.

Now what?

If either of Assembly's HBV drugs becomes modestly successful, this company's recent $381 million market cap will more than double, more than once. We'll get a clearer picture when the company describes its poster presentations at AASLD on Monday, Nov. 11, 2019.

After burning through $46 million in the first half of 2019, the company finished June with $174 million in cash and securities. That's only enough to fund the company's expanding operations into the beginning of 2021, which means a dilutive secondary offering is probably right around the corner.

(Analyst Disclosures: None, no ownership or relationship.)


Click to enlarge

Risk was on this past week, on the back of the promise of the rumor of a rumor of a seed stage of a trade deal.

Click to enlarge

___

Equities Contributor: Chris Lahiji

Source: Equities News

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer. The author of this article, or a firm that employs the author, is a holder of the following securities mentioned in this article : None

Companies

Symbol Name Price Change % Volume
ASMB Assembly Biosciences Inc. 13.00 0.93 7.71 711,211 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

Blockchain in Healthcare - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Health - How Blockchain technology can make health care systems more patient-centric and sustainable